Thu: Tel Aviv 25 Index up 2.5% on week

The market was given a tonic by the end of the Gaza operation as Israel Chemicals and the telcos led the rises.

The Tel Aviv Stock Exchange (TASE) rose today. The Tel Aviv 25 Index rose 0.20% to 1,211.03 points, the Tel Aviv 100 Index rose 0.33% to 1,067.99 points, and the BlueTech 50 Index rose 0.75% to 331.09 points. Turnover was NIS 865.1 million.

The TASE rose across the board following the cease-fire agreement to end Operation Pillar of Defense in Gaza. European markets rose today while Wall Street is closed for the Thanksgiving holiday. The Tel Aviv 25 Index rose 2.5% for the week, after falling by precisely the same percentage last week.

In the bond market, long-term Shahar unlinked government bonds were unchanged and long-term Galil CPI-linked bonds rose by up to 0.2%. The corporate bond benchmark Tel-Bond 20 Index rose 0.04%.

In the foreign currency market, Bank of Israel set the shekel-dollar representative exchange rate at NIS 3.867/$, down 1.25% on yesterday's rate, and set the shekel-euro representative exchange rate at NIS 4.983/€, down 0.64%.

In the stock market, Partner Communications Ltd. (Nasdaq: PTNR; TASE: PTNR) rose 2% after publishing its third quarter financials yesterday. Bezeq Israeli Telecommunication Co. Ltd. (TASE: BEZQ) rose 2.2% after announcing that it had reached a wholesale services agreement with Partner. A similar agreement with Cellcom Israel Ltd. (NYSE:CEL; TASE:CEL) is also expected. Cellcom rose 2% today.

Israel Chemicals (TASE: CHIM) rose 2.1% after Barclays gave it a positive outlook.

Bank Leumi (TASE: LUMI) rose 1% on the day's highest trading volume of NIS 54 million.

Outside of the Tel Aviv 25 Index, Clal Biotechnology Industries Ltd. (TASE: CBI) rose 7.8% following trial results announced by portfolio company Curetech in which it has a 12% stake.

Spectronix Ltd. (TASE: SPCT) rose 8.5% after publishing its financials and Proteologics Ltd. (TASE: PRTL) jumped 21.8% on the news that XTL Biopharmaceuticals Ltd. (Pink Sheets:XTLBY); TASE:XTL) had acquired a 31% stake in the drug developer from Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) at a 20% premium.

Published by Globes [online], Israel business news - www.globes-online.com - on November 22, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018